This is a standard proxy filing for an annual shareholder meeting. No immediate trading action is required. Monitor the voting results for the shareholder proposal on an independent chair, as a significant vote could signal governance concerns.
ABBV drugs
ABBV drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 24 $203.51entry
- T+1 · 8mo ago +0.96%α +0.40% · $205.48
- T+5 · 8mo ago +5.99%α +6.41% · $215.70
- T+20 · 7mo ago −1.48%α −10.38% · $200.50
- T+60 · 5mo ago +6.38%α −7.95% · $216.49
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AbbVie Inc. is holding its 2026 Annual Meeting for shareholders. The proxy statement includes proposals to elect four Class II directors, ratify the independent auditor, approve executive compensation (Say on Pay), amend the certificate of incorporation to eliminate supermajority voting, and vote on a shareholder proposal to adopt an independent chair. This is routine corporate governance material.
Key Facts
- Annual meeting scheduled for May 8, 2026.
- Four Class II directors are up for election: Jennifer L. Davis, Melody B. Meyer, Robert A. Michael, and Frederick H. Waddell.
- Proposal to ratify Ernst & Young LLP as the independent auditor for 2026.
- Say on Pay advisory vote on executive compensation.
- Management proposal to amend the certificate of incorporation to eliminate supermajority voting.
- Shareholder proposal to adopt a policy requiring an independent chair.
Financial Impact
No direct financial impact from this filing.
Risk Factors
- A significant vote against management on the independent chair proposal could indicate shareholder dissatisfaction with current governance, potentially leading to future governance changes or activist pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001104659-26-033391 |
| Document: 0001104659-26-033391-index-headers.html | 0001104659-26-033391 |
| Document: 0001104659-26-033391-index.html | 0001104659-26-033391 |
| Document: 0001104659-26-033391.txt | 0001104659-26-033391 |
Track record
22 reports on ABBV
6 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +27.21% at T+60 after the Apr 29, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $293.89 Now $294.55 +0.22% settles Feb 8
- Nov 2, 202614d ago 8-K Neutral 2/10 Entry $286.00 Now $294.55 +2.99% settles Feb 1
- Oct 30, 202617d ago 8-K Bullish 6/10 Entry $294.89 Now $294.55 −0.12% settles Jan 28
- Oct 29, 202618d ago Court Ruling Bullish 7/10 Entry $294.89 Now $294.55 −0.12% settles Jan 28
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $282.68 Now $294.55 +4.20% settles Jan 14
- Oct 15, 20264w ago 8-K Neutral 2/10 Entry $285.42 Now $294.55 +3.20% settles Jan 13
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $265.06 Now $294.55 +11.12% settles Dec 31
- Sep 28, 20267w ago Court Ruling Neutral 2/10 Entry $263.29 Now $294.55 +11.87% settles Dec 23
- Sep 14, 20269w ago Court Ruling Neutral Not scored Entry $261.43 Now $294.55 +12.67% settles Dec 9
- Sep 3, 202610w ago 8-K Neutral 4/10 Entry $260.21 Now $294.55 +13.20% settles Nov 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers